CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use
Standard
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. / Mocroft, Amanda; Phillips, Andrew N; Gatell, Jose; Horban, Andrej; Ledergerber, Bruno; Zilmer, Kai; Jevtovic, Djordje; Maltez, Fernando; Podlekareva, Daria; Lundgren, Jens D; EuroSIDA in EuroCoord.
In: AIDS, Vol. 27, No. 6, 27.03.2013, p. 907-18.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use
AU - Mocroft, Amanda
AU - Phillips, Andrew N
AU - Gatell, Jose
AU - Horban, Andrej
AU - Ledergerber, Bruno
AU - Zilmer, Kai
AU - Jevtovic, Djordje
AU - Maltez, Fernando
AU - Podlekareva, Daria
AU - Lundgren, Jens D
AU - EuroSIDA in EuroCoord
AU - van Lunzen, Jan
PY - 2013/3/27
Y1 - 2013/3/27
N2 - BACKGROUND: CD4 cell count and viral loads are used in clinical trials as surrogate endpoints for assessing efficacy of newly available antiretrovirals. If antiretrovirals act through other pathways or increase the risk of disease this would not be identified prior to licensing. The aim of this study was to investigate the CD4 cell count and viral load-specific rates of fatal and nonfatal AIDS and non-AIDS events according to current antiretrovirals.METHODS: Poisson regression was used to compare overall events (fatal or nonfatal AIDS, non-AIDS or death), AIDS events (fatal and nonfatal) or non-AIDS events (fatal or nonfatal) for specific nucleoside pairs and third drugs used with more than 1000 person-years of follow-up (PYFU) after 1 January 2001.RESULTS: Nine thousand, eight hundred and one patients contributed 42372.5 PYFU, during which 1203 (437 AIDS and 766 non-AIDS) events occurred. After adjustment, there was weak evidence of a difference in the overall events rates between nucleoside pairs (global P-value = 0.084), and third drugs (global P-value = 0.031). As compared to zidovudine/lamivudine, patients taking abacavir/lamivudine [adjusted incidence rate ratio (aIRR) 1.22; 95% CI 0.99-1.49] and abacavir and one other nucleoside [aIRR 1.51; 95% CI 1.14-2.02] had an increased incidence of overall events. Comparing the third drugs, those taking unboosted atazanavir had an increased incidence of overall events compared with those taking efavirenz (aIRR 1.46; 95% CI 1.09-1.95).CONCLUSION: There was little evidence of substantial differences between antiretrovirals in the incidence of clinical disease for a given CD4 cell count or viral load, suggesting there are unlikely to be major unidentified adverse effects of specific antiretrovirals.
AB - BACKGROUND: CD4 cell count and viral loads are used in clinical trials as surrogate endpoints for assessing efficacy of newly available antiretrovirals. If antiretrovirals act through other pathways or increase the risk of disease this would not be identified prior to licensing. The aim of this study was to investigate the CD4 cell count and viral load-specific rates of fatal and nonfatal AIDS and non-AIDS events according to current antiretrovirals.METHODS: Poisson regression was used to compare overall events (fatal or nonfatal AIDS, non-AIDS or death), AIDS events (fatal and nonfatal) or non-AIDS events (fatal or nonfatal) for specific nucleoside pairs and third drugs used with more than 1000 person-years of follow-up (PYFU) after 1 January 2001.RESULTS: Nine thousand, eight hundred and one patients contributed 42372.5 PYFU, during which 1203 (437 AIDS and 766 non-AIDS) events occurred. After adjustment, there was weak evidence of a difference in the overall events rates between nucleoside pairs (global P-value = 0.084), and third drugs (global P-value = 0.031). As compared to zidovudine/lamivudine, patients taking abacavir/lamivudine [adjusted incidence rate ratio (aIRR) 1.22; 95% CI 0.99-1.49] and abacavir and one other nucleoside [aIRR 1.51; 95% CI 1.14-2.02] had an increased incidence of overall events. Comparing the third drugs, those taking unboosted atazanavir had an increased incidence of overall events compared with those taking efavirenz (aIRR 1.46; 95% CI 1.09-1.95).CONCLUSION: There was little evidence of substantial differences between antiretrovirals in the incidence of clinical disease for a given CD4 cell count or viral load, suggesting there are unlikely to be major unidentified adverse effects of specific antiretrovirals.
KW - Acquired Immunodeficiency Syndrome
KW - Adult
KW - Anti-Retroviral Agents
KW - CD4 Lymphocyte Count
KW - Cohort Studies
KW - Female
KW - Humans
KW - Incidence
KW - Male
KW - Middle Aged
KW - Prospective Studies
KW - Survival Analysis
KW - Viral Load
U2 - 10.1097/QAD.0b013e32835cb766
DO - 10.1097/QAD.0b013e32835cb766
M3 - SCORING: Journal article
C2 - 23698060
VL - 27
SP - 907
EP - 918
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 6
ER -